Hyperthyroidism Global Clinical Market Research Report, Analysis, Opportunities, Forecast, Revenue, Trends, Value : Ken Research

1

• Malignancy Associated With Hyperthyroidism Market
  Outlook Ken Research

2

• According to the study HYPERTHYROIDISM GLOBAL
  CLINICAL TRIALS REVIEW, H1, 2018, among the most
  popular remedies is radioactive iodine (RAI)
  which is taken orally and gets absorbed by the
  thyroid gland. It is meant to destroy the hyper
  functioning thyroid tissues which can help reduce
  symptoms. RAI is generally safe and has been used
  for decades and is still undergoing research by
  scientists who are attempting to better
  understand the most commonly used Iodine-131.
• Hyperthyroidism is a condition in which an
  overactive thyroid gland is producing an
  excessive amount of thyroid hormones, such as
  thyroxine and triiodothyronine that circulate in
  the blood. Common symptoms of hyperthyroidism
  include restlessness, agitation, anxiety, weight
  loss despite increased appetite, intolerance to
  heat and frequent bowel movements among others.
  Graves disease I s the most common cause of
  hyperthyroidism and can be associated with eye
  disease (Graves opthalmopathy).

3

• Patients with hyperthyroidism have multiple
  options for treatment and management depending on
  factors like age, physical condition, underlying
  causes of the disease, personal preference and
  severity of the condition. However, modern study
  is exploring the possibility of hyperthyroidism
  being connected to cancerous tissues. Thyroid
  cancer starts in the thyroid gland and its
  prevalence in patients with hyperthyroidism
  varies. This variation stems from factors like
  extent of histological examination of removed
  thyroid tissue, the cause and extent of
  hyperthyroidism, criteria for choosing surgery in
  the treatment of hyperthyroidism and geographical
  differences in cancer rates. The overall
  prevalence of thyroid cancer found during surgery
  in patients with hyperthyroidism ranges from a
  low level to a significant level. The majority of
  carcinomas reported in these studies were micro
  carcinomas, the clinical significance of which is
  uncertain. Papillary carcinoma was the most
  frequently reported cancer type.

4

• Many global associations have been established in
  response to the growing concern. These
  institutions annually focus on themes thereby
  bringing expertise to the table to augment
  developments in the field for instance, The
  Asia-Pacific Society of Thyroid Surgery will meet
  in December 2018 to discuss thyroid surgery. It
  will discuss newly developed technologies
  including molecular diagnoses, intraoperative
  neuromonitoring, endoscopic and robotic surgery
  among others. Researchers have also come together
  and experimented with Iodine-131 on mice. Other
  developments are also taking place in similar
  radiology therapies and nuclear medicine. Such
  future prospects aim to be more target oriented
  and minimize after effects of these treatments
  such as under-activity of the thyroid gland after
  consumption of radioactive iodine. The American
  Thyroid Association is among the leading
  institutions in the world that specializes in
  thyroid research.

5

• Studies are also trying to establish connections
  between the causes of hyperthyroidism and
  cancerous tissues that develop in the thyroid
  gland. The link between Graves hyperthyroidism
  and cancer remains debatable with the cancer
  rates appearing to range widely. Hence,
  researchers state that clinicians that treat
  hyperthyroidism patients should be aware of the
  outlined malignancy risk involved. Every
  suspicious thyroid nodule that is linked to
  hyperthyroidism should be carefully evaluated. In
  addition, nuclear medicine and radiology are also
  picking up pace to improve their efficiency.

6

• To know more, click on the link below
• https//www.kenresearch.com/healthcare/general-hea
  lthcare/hyperthyroidism-global-clinical/150988-91.
  html
• Related Report
• https//www.kenresearch.com/healthcare/pharmaceuti
  cals/hyperthyroidism-global-clinical/35768-91.html
  
• Contact Us
• Ken Research
• Ankur Gupta, Head Marketing Communications
• sales_at_kenresearch.com
• 91-9015378249

7
(No Transcript)